Table 2.

Vaccine strategies used for HCV vaccine development

Vaccine recipients for assessing immunogenicity
		Immune response–induced		Humans
Rodents or macaques	Chimpanzees	Not at risk for HCV	At risk for HCV	Neutralizing antibodies	T cells
DNA-based	DNA-based			Not tested	Yes
VLPs with various proteins	VLPs with E1, E2, core	VLPs with E1, E2, core		No	Yes
Adjuvanted HCV proteins or truncated E1E2	Adjuvanted HCV proteins	Adjuvanted HCV core, adjuvanted E1E2		Yes, for some	Yes
Recombinant viral vectors	Recombinant viral vectors	Recombinant viral vectors	Recombinant viral vectors	Yes, for some	Yes
Whole virus				Yes	Not tested
Class I HCV peptide epitopes				No	Yes
Peptides incorporated in lysosomes				No	Yes

(HCV) hepatitis C virus, (VLP) virus-like particle.